ReNerve Limited (RNV.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.092 (-1.08%) as of
Key statistics
- Market cap
- 15.96M
- EPS (TTM)
- -0.0300
- Dividend yield
- 0.00%
- 52-week range
- 0.0680 – 0.2200
- Revenue (TTM)
- 510.36k
- Profit margin
- 0.00%
- Volume
- 227.69k
About ReNerve Limited
ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers Empliq Dermal, an acellular dermal matrix (ADM) sourced from donated human skin and designed to replace lost or damaged dermal tissue; bionic nerve, a novel combination polymer technology; and Nerve Guide Matrix for treating more severe nerve injuries but eliminating the need for patients to undergo additional sural nerve harvesting under the NervAlign brand. The company was incorporated in 2016 and is headquartered in Northcote, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Northcote, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.